Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2016-08-29T12:08:08Z | - |
dc.date.available | 2016-08-29T12:08:08Z | - |
dc.date.issued | 2015 | * |
dc.identifier.issn | 0902-4441 | * |
dc.identifier.other | OAK-14982 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/230586 | - |
dc.description.abstract | This study aimed to determine the objective response, toxicity, and clinical outcome of weekly rituximab consolidation after four cycles of R-CHOP21 in very elderly patients with DLBCL. A prospective, multi-institutional phase II trial was conducted on patients with previously untreated CD20+ DLBCL who were older than 70 yr. Patients were treated with four cycles of R-CHOP21 followed by weekly consolidation with rituximab (375mg/m2, four times infusion) (NCT01181999). We also compared the clinical outcomes with an historical case-matched control group treated conventionally with six cycles of R-CHOP21. A total of 51 patients with newly diagnosed DLBCL were enrolled at 15 institutes between June 2010 and September 2013. The median age was 76 yr (range: 70-89). Forty-one of the 51 patients completed the planned rituximab consolidation (R-consolidation). The overall response rate was 78.4%, comprising 74.5% with a complete response and 3.9% with a partial response. After a median follow-up of 20.3 months, 2-yr progression-free survival and overall survival were 63.9% and 68.7%, respectively. No serious toxicities were reported during rituximab consolidation. Weekly rituximab consolidation following four cycles of R-CHOP21 resulted in an acceptable response with high tolerability and could be a good compromise between efficacy and safety for elderly patients with DLBCL. © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | * |
dc.language | English | * |
dc.publisher | Blackwell Publishing Ltd | * |
dc.subject | Diffuse large B-cell lymphoma | * |
dc.subject | Elderly | * |
dc.subject | Rituximab consolidation | * |
dc.title | Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL) | * |
dc.type | Article | * |
dc.relation.issue | 6 | * |
dc.relation.volume | 94 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 504 | * |
dc.relation.lastpage | 510 | * |
dc.relation.journaltitle | European Journal of Haematology | * |
dc.identifier.doi | 10.1111/ejh.12459 | * |
dc.identifier.wosid | WOS:000354370400006 | * |
dc.identifier.scopusid | 2-s2.0-84929070416 | * |
dc.author.google | Jung S.-H. | * |
dc.author.google | Lee J.-J. | * |
dc.author.google | Kim W.S. | * |
dc.author.google | Lee W.-S. | * |
dc.author.google | Do Y.R. | * |
dc.author.google | Oh S.Y. | * |
dc.author.google | Kim M.K. | * |
dc.author.google | Mun Y.-C. | * |
dc.author.google | Shin H.-J. | * |
dc.author.google | Kwak J.-Y. | * |
dc.author.google | Kang H.J. | * |
dc.author.google | Won J.H. | * |
dc.author.google | Kwon J.H. | * |
dc.author.google | Park E. | * |
dc.author.google | Suh C. | * |
dc.author.google | Yang D.-H. | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |